IP Library Granted Patent US 9,328,374
Granted Patent B2
US 9,328,374 · App. 14/130,605 · Granted May 3, 2016

Selective culture medium and method for detecting carbapenem-resistant bacteria in a test sample

Inventors: Patrice Nordmann (Le Kremlin Bicêtre, FR); Laurent Poirel (Le Kremlin Bicêtre, FR); Delphine Girlich (Le Kremlin Bicêtre, FR)
Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM); UNIVERSITE PARIS SUD; ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
C12Q1/18C12Q1/045
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,328,374
App. No.
14/130,605
Granted
May 3, 2016
Kind
B2
Abstract

The present invention relates to a culture medium comprising a carbapenem, a carbapenemase activator and a M-type penicillin. It also relates to a method for detecting carbapenem-resistant bacteria in a test sample using said culture medium.

Claims (12)

1. A method for detecting carbapenem-resistant bacteria in a test sample comprising the following successive steps:

a) inoculating a culture medium with said test sample, wherein said culture medium comprises a carbapenem, a M-type penicillin and a carbapenemase activator selected from the group consisting of divalent cations and mixtures thereof, and is suitable for growth of class A, B and D carbapenemase-producing bacteria; and

b) incubating said culture medium under conditions suitable for growth of carbapenem-resistant bacteria; and

c) detecting colonies formed on said culture medium, wherein detection of colonies is an indication of the presence in said test sample of at least one species of carbapenem-resistant bacteria producing a carbapenemase belonging to class A, B or D.

2. The method according to claim 1 , wherein the carbapenem is selected from the group consisting of ertapenem, biapenem, doripenem, imipenem, meropenem, tebipenem, panipenem and mixtures thereof.

3. The method according to claim 1 , wherein the carbapenem is ertapenem and the concentration of ertapenem in the culture medium is from 0.1 to 1 μg/ml.

4. The method according to claim 1 , wherein the carbapenem is doripenem and the concentration of doripenem in the culture medium is from 0.01 to 0.1 μg/ml.

5. The method according to claim 1 , wherein the carbapenemase activator is a divalent cation selected from the group consisting of zinc, magnesium, manganese and mixtures thereof.

6. The method according to claim 1 , wherein the divalent cation is zinc.

7. The method according to claim 1 , wherein the M-type penicillin is selected from the group consisting of cloxacillin, dicloxacillin, flucloxacillin, oxacillin, methicillin, nafcillin and mixtures thereof.

8. The method according to claim 1 , wherein the M-type penicillin is cloxacillin.

9. The method according claim 1 , wherein the carbapenem is ertapenem, the divalent cation is zinc, and the M-type penicillin is cloxacillin.

Assignments (3)
MERGER Recorded Aug 17, 2022
From: UNIVERSITE PARIS-SUD
To: UNIVERSITÉ PARIS-SACLAY
Reel/Frame 060831/0318 →
CHANGE OF NAME Recorded Mar 4, 2016
From: UNIVERSITE PARIS SUD (PARIS 11)
To: UNIVERSITE PARIS SUD
Reel/Frame 038061/0776 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2014
From: GIRLICH, DELPHINE; POIREL, LAURENT; NORDMANN, PATRICE
To: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); UNIVERSITE PARIS SUD (PARIS 11); ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
Reel/Frame 032351/0345 →
Priority Claims (1)
EP 11305860 · Jul 5, 2011 · regional
Continuity (2)
Provisional Application 61507234 · Jul 13, 2011
Related Publication 20140178922A1 · Jun 26, 2014